Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autism Spectrum Disorder01:19

Autism Spectrum Disorder

Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Modeling in Therapy01:26

Modeling in Therapy

Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of data imputation strategies in complex, deeply-phenotyped data sets: the case of the EU-AIMS Longitudinal European Autism Project.

BMC medical research methodology·2022
Same author

Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers.

Molecular autism·2021
Same author

Heterotopia in Individuals with 22q11.2 Deletion Syndrome.

AJNR. American journal of neuroradiology·2021
Same author

The Neuroanatomy of Autism Spectrum Disorder Symptomatology in 22q11.2 Deletion Syndrome.

Cerebral cortex (New York, N.Y. : 1991)·2018
Same author

Neurodevelopmental origins of abnormal cortical morphology in dissociative identity disorder.

Acta psychiatrica Scandinavica·2017
Same author

Sex differences in frontal lobe connectivity in adults with autism spectrum conditions.

Translational psychiatry·2017
Same journal

Patients with hereditary hemorrhagic telangiectasia have significantly reduced overall survival-And likely by a greater magnitude than we realize.

Journal of internal medicine·2026
Same journal

Social jet lag is associated with incident cardiovascular disease independent of sleep duration and cardiac genetic risk.

Journal of internal medicine·2026
Same journal

Multicenter validation of a severity index model for predicting postoperative acute kidney injury.

Journal of internal medicine·2026
Same journal

The changing epidemiology of human type 2 diabetes-associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities.

Journal of internal medicine·2026
Same journal

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same journal

Authors' reply: Myasthenia gravis following the initiation of statin therapy.

Journal of internal medicine·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells (NPCs)
10:47

Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells (NPCs)

Published on: March 2, 2018

Developing new pharmacotherapies for autism.

C Ecker1, W Spooren, D Murphy

  • 1Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, London, UK.

Journal of Internal Medicine
|July 20, 2013
PubMed
Summary
This summary is machine-generated.

Developing targeted autism spectrum disorder (ASD) pharmacotherapies is challenging due to ASD's complexity. New insights into genetics and neurobiology offer opportunities for personalized treatments and a strategic framework for drug development.

Keywords:
autismbiomarkersdrug developmentpersonalized medicinetranslational research

More Related Videos

Strategies for Assessing Autistic-Like Behaviors in Mice
07:38

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

Probing the Brain in Autism Using fMRI and Diffusion Tensor Imaging
12:21

Probing the Brain in Autism Using fMRI and Diffusion Tensor Imaging

Published on: September 12, 2011

Related Experiment Videos

Last Updated: May 9, 2026

Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells (NPCs)
10:47

Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells (NPCs)

Published on: March 2, 2018

Strategies for Assessing Autistic-Like Behaviors in Mice
07:38

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

Probing the Brain in Autism Using fMRI and Diffusion Tensor Imaging
12:21

Probing the Brain in Autism Using fMRI and Diffusion Tensor Imaging

Published on: September 12, 2011

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Autism spectrum disorder (ASD) presents significant challenges for pharmacotherapy development due to its complex genetic basis, diverse neurobiological characteristics, and varied symptom presentation.
  • Emerging research offers new avenues for developing targeted and individualized pharmacological interventions for ASD.
  • Understanding the genetic and neurobiological underpinnings of ASD is crucial for advancing treatment strategies.

Purpose of the Study:

  • To review current insights into the etiology and neurobiology of ASD, focusing on genetic variants affecting synaptic function and neurobiological differences.
  • To propose a strategic framework for developing targeted pharmacotherapies for ASD, integrating research findings into clinical applications.
  • To introduce the European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS) Initiative as a platform for translational research in ASD.

Main Methods:

  • Review of genetic variants influencing synaptic structure and function in ASD.
  • Analysis of neuroanatomical, chemical, and connectivity differences in the brains of individuals with ASD.
  • Development of a strategic framework for translating research into clinical applications, including the use of animal models and cellular assays.
  • Presentation of the EU-AIMS Initiative, a collaborative platform for translational research.

Main Results:

  • Identification of key genetic variants and neurobiological differences contributing to ASD etiology.
  • Establishment of a framework for targeted pharmacotherapy development, emphasizing early-stage research and testing.
  • Initiation of the EU-AIMS Initiative to foster integrated, collaborative translational research in ASD.

Conclusions:

  • Characterizing genotypic and phenotypic differences in ASD can enable subgroup stratification for tailored interventions.
  • A structured approach, from basic research to clinical trials, is essential for developing effective ASD pharmacotherapies.
  • The EU-AIMS Initiative represents a significant step towards a personalized approach to diagnosing and treating ASD through collaborative research.